[go: up one dir, main page]

AR114133A2 - Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno - Google Patents

Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno

Info

Publication number
AR114133A2
AR114133A2 ARP190100701A ARP190100701A AR114133A2 AR 114133 A2 AR114133 A2 AR 114133A2 AR P190100701 A ARP190100701 A AR P190100701A AR P190100701 A ARP190100701 A AR P190100701A AR 114133 A2 AR114133 A2 AR 114133A2
Authority
AR
Argentina
Prior art keywords
triaza
dioxa
pyrrolidin
tetraciclo
heptacose
Prior art date
Application number
ARP190100701A
Other languages
English (en)
Original Assignee
Cti Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cti Biopharma Corp filed Critical Cti Biopharma Corp
Publication of AR114133A2 publication Critical patent/AR114133A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno (Compuesto I), de fórmula (1), del cual se descubrió que tiene propiedades mejoradas.
ARP190100701A 2008-12-11 2019-03-20 Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno AR114133A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11

Publications (1)

Publication Number Publication Date
AR114133A2 true AR114133A2 (es) 2020-07-22

Family

ID=41666397

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090104834A AR074724A1 (es) 2008-12-11 2009-12-11 Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno
ARP190100701A AR114133A2 (es) 2008-12-11 2019-03-20 Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP090104834A AR074724A1 (es) 2008-12-11 2009-12-11 Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno

Country Status (23)

Country Link
US (2) US8980873B2 (es)
EP (1) EP2376499B1 (es)
JP (1) JP5669748B2 (es)
KR (1) KR101729918B1 (es)
CN (1) CN102282148B (es)
AR (2) AR074724A1 (es)
AU (1) AU2009325147B2 (es)
BR (1) BRPI0922736B1 (es)
CA (1) CA2746058C (es)
DK (1) DK2376499T3 (es)
ES (1) ES2536558T3 (es)
HR (1) HRP20150428T1 (es)
IL (3) IL213418A0 (es)
MX (1) MX2011006206A (es)
MY (1) MY160005A (es)
NZ (1) NZ593223A (es)
PL (1) PL2376499T3 (es)
PT (1) PT2376499E (es)
RU (1) RU2527970C2 (es)
SG (1) SG171907A1 (es)
TW (1) TWI449705B (es)
WO (1) WO2010068181A1 (es)
ZA (1) ZA201104032B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068182A1 (en) * 2008-12-11 2010-06-17 S*Bio Pte Ltd 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
MY160005A (en) 2008-12-11 2017-02-15 Cti Biopharma Corp 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
KR101673979B1 (ko) 2012-04-13 2016-11-08 리안윤강 진강 해신 파머수티컬 코. 엘티디. 화합물 jk12a 및 그 제조
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
KR20040008175A (ko) * 2001-05-14 2004-01-28 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로(10.3.1.02,11.04,9)-헥사데카-2(11),3,5,7,9-펜타엔의 시트르산염 및 그의 제약 조성물
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
DE60209929T2 (de) * 2001-11-29 2006-11-16 Pfizer Products Inc., Groton Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen
KR101499594B1 (ko) * 2005-11-16 2015-03-09 씨티아이 바이오파마 코포레이션 산소가 결합된 피리미딘 유도체
MY160005A (en) 2008-12-11 2017-02-15 Cti Biopharma Corp 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt

Also Published As

Publication number Publication date
MX2011006206A (es) 2011-07-20
RU2011126173A (ru) 2013-01-20
TWI449705B (zh) 2014-08-21
CA2746058A1 (en) 2010-06-17
US8980873B2 (en) 2015-03-17
PT2376499E (pt) 2015-06-03
JP5669748B2 (ja) 2015-02-12
BRPI0922736B1 (pt) 2022-02-22
NZ593223A (en) 2013-08-30
RU2527970C2 (ru) 2014-09-10
MY160005A (en) 2017-02-15
AU2009325147B2 (en) 2014-08-14
US20110294831A1 (en) 2011-12-01
AR074724A1 (es) 2011-02-09
ZA201104032B (en) 2012-08-29
CA2746058C (en) 2016-05-17
US20150322084A1 (en) 2015-11-12
WO2010068181A8 (en) 2011-08-18
EP2376499B1 (en) 2015-02-25
AU2009325147A1 (en) 2011-06-23
EP2376499A1 (en) 2011-10-19
IL250310A0 (en) 2017-03-30
BRPI0922736A2 (pt) 2017-10-31
ES2536558T3 (es) 2015-05-26
TW201028426A (en) 2010-08-01
WO2010068181A1 (en) 2010-06-17
BRPI0922736A8 (pt) 2021-11-09
DK2376499T3 (en) 2015-05-04
KR101729918B1 (ko) 2017-04-25
JP2012511571A (ja) 2012-05-24
HRP20150428T1 (xx) 2015-06-19
PL2376499T3 (pl) 2015-07-31
IL289379A (en) 2022-02-01
HK1161877A1 (en) 2012-08-10
IL213418A0 (en) 2011-07-31
SG171907A1 (en) 2011-07-28
CN102282148B (zh) 2014-12-24
CN102282148A (zh) 2011-12-14
KR20110106344A (ko) 2011-09-28
US9624242B2 (en) 2017-04-18

Similar Documents

Publication Publication Date Title
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
EA201270216A1 (ru) Фармацевтический состав
MA37940A2 (fr) Nouveaux dérivés bicycliques
AR114133A2 (es) Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno
CR20110432A (es) Pirimidinas fusionadas
EA201270308A1 (ru) Конъюгаты димеров пирроло [1,4]бензодиазепина в качестве противоракового средства
EA201070988A1 (ru) Противовирусные терапевтические средства
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
CR20110047A (es) Compuestos de cobre nanoparticulados
MA35664B1 (fr) Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one
BR112012008020A2 (pt) máquina de perfuração.
EA201170168A1 (ru) Комплекс (минерал-аминокислота)-полисахарид
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
EA201590979A1 (ru) Способы и промежуточные химические соединения для получения фармацевтических средств
NI200900151A (es) Nuevo procedimiento de síntesis de la agomelatina.
UA107455C2 (uk) Похідні індолу як протиракові агенти
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
BR112012031340A2 (pt) derivados de cianoquinolina
AR114134A2 (es) Sal de maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno
PH12015501146A1 (en) Hydantoin derivative
EA201270237A1 (ru) Способ получения 1-бензил-3-гидроксиметил-1н-индазола и его производных и необходимые промежуточные соединения, содержащие магний
EA201270390A1 (ru) 1,2,4-триазин, который может быть использован в качестве ускорителя вулканизации, и способ его получения
DOP2011000296A (es) Compuesto de pirazol
CY1112501T1 (el) Φαρμακευτικες συνθεσεις περιεχουσες λεφλουνομιδη

Legal Events

Date Code Title Description
FB Suspension of granting procedure